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Introduction
Acute kidney injury (AKI) is a very common clinical condition characterized by a rapid fall in glomerular 
filtration rate, often as a result of  an ischemic or nephrotoxic renal insult (1–3). AKI is associated with a 
high risk for mortality, subsequent chronic kidney disease (CKD), end-stage renal disease (ESRD), and oth-
er types of  organ failure. The incidence of  AKI is increasing worldwide, especially in the elderly population 
(4, 5), making AKI a major public health issue and an enormous global economic burden. In the United 
States alone, AKI affects more than 1.2 million patients per year during hospital stays, and kills 300,000 
people annually; moreover, the population incidence rate of  AKI is increasing an average of  10% per year 
(1, 4). While epidemiological studies showed that the clinical outcomes for AKI are worse in the elderly 
than in the young (5), the reasons for the failure of  the aged kidney to repair itself  and for its progression 
to CKD or ESRD after AKI have not been fully investigated. Thus, no effective therapeutic tools have been 
developed to improve survival after AKI in the elderly.
Acute kidney injury (AKI) is a common clinical condition defined as a rapid decline in kidney 
function. AKI is a global health burden, estimated to cause 2 million deaths annually worldwide. 
Unlike AKI in the young, which is reversible, AKI in the elderly often leads to end-stage renal 
disease, and the mechanism that prevents kidney repair in the elderly is unclear. Here we 
demonstrate that aged but not young mice developed multiple tertiary lymphoid tissues (TLTs) in 
the kidney after AKI. TLT size was associated with impaired renal function and increased expression 
of proinflammatory cytokines and homeostatic chemokines, indicating a possible contribution 
of TLTs to sustained inflammation after injury. Notably, resident fibroblasts from a single lineage 
diversified into p75 neurotrophin receptor+ (p75NTR+) fibroblasts and homeostatic chemokine–
producing fibroblasts inside TLTs, and retinoic acid–producing fibroblasts around TLTs. Deletion 
of CD4+ cells as well as late administration of dexamethasone abolished TLTs and improved renal 
outcomes. Importantly, aged but not young human kidneys also formed TLTs that had cellular and 
molecular components similar to those of mouse TLTs. Therefore, the inhibition of TLT formation 
may offer a novel therapeutic strategy for AKI in the elderly.
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Inflammation is a crucial contributor to cellular injury and malfunction (2, 3, 6, 7), and inflammatory 
cell infiltration is commonly observed in chronic diseases. Although most inflammatory cells are not spa-
tially and functionally organized, chronic infiltrates sometimes organize into clusters that are enriched in 
T and B cells. These ectopic lymphoid structures in nonlymphoid organs are referred to as tertiary lym-
phoid tissues (TLTs) to distinguish them from secondary lymphoid organs (SLOs) such as lymph nodes 
(8–11). TLTs function as local sites of  antigen presentation, clonal expansion, and lymphocyte activation, 
all of  which discriminate TLTs from chronic infiltrates (8, 10, 11). TLTs are supported structurally by non-
hematopoietic stromal cells, fibroblasts in particular (8), although their function, developmental origin, and 
phenotypic heterogeneity remain unclear. TLTs often develop in a variety of  chronic inflammatory lesions 
including autoimmunity, persistent infection, atherosclerosis, and cancer (8–11). Of  particular interest, the 
role of  TLTs is context dependent and can be beneficial or detrimental to the host. During infection, TLTs 
are often beneficial and are associated with pathogen clearance and increased survival (12). TLTs are detri-
mental when they destroy normal tissue and exacerbate autoimmune diseases and chronic rejection (8–11), 
suggesting that TLTs may serve as a therapeutic target in the latter contexts (13).
Here we demonstrated that aged mice, but not young mice, developed multiple renal TLTs in 3 kidney 
injury models, which promoted inflammation and might compromise kidney regeneration, and that the 
abolishment of  TLTs improved renal outcomes. Notably, fibroblasts from a single lineage differentiated 
into several distinct phenotypes in response to their microenvironment, and these fibroblasts underlay TLT 
formation. Importantly, age-dependent TLT formation is also observed in human kidneys, and the cellular 
and molecular components of  TLTs in humans are similar to those in mice. Thus, a mechanism similar to 
that observed in mice might contribute to the maladaptive repair of  kidneys in elderly humans.
Results
Aged kidneys show multiple TLTs and sustained inflammation in response to injuries. Before the induction of  AKI, 
no difference was observed in the renal function or morphology between young (8-week-old) and aged 
(12-month-old) mice (Supplemental Figure 1; supplemental material available online with this article; 
doi:10.1172/jci.insight.87680DS1). To evaluate the impact of  aging on the prognosis of  AKI, we induced 
unilateral ischemic reperfusion injury (IRI), and found that aged kidneys showed interstitial fibrosis, delayed 
regeneration, and persistent inflammation (Figure 1, A and B, and Supplemental Figure 2, A and B). 
Notably, aged but not young kidneys exhibited significant inflammatory cell aggregates after IRI (Figure 1A); 
these aggregates were distributed in the cortex and along the hilus of  the kidney (Supplemental Figure 
2C), and also contained arteries, lymphatic vessels, and high endothelial venules (HEVs) (Figure 1, C and 
D). T cells and B cells were predominant and intermingled throughout the aggregates (Figure 1E). The 
T cells consisted mainly of  CD4+ T cells (Supplemental Figure 3, A and B). Some dendritic cells were also 
identified as the third population (Supplemental Figure 3, C and D). These aggregates contained a large 
number of  proliferative (Ki67+) cells (Figure 1F), some of  which were also positive for CD3ε and B220 
(Supplemental Figure 3, E–G). Furthermore, we also detected T cells positive for programmed death-1 
(PD-1, CD279), a negative checkpoint regulator expressed on antigen-stimulated T cells (14, 15), within 
these aggregates (Supplemental Figure 3H). These results suggest that the T-B cell interactions occurred 
within these lymphoid aggregates, which therefore allows us to define these lymphoid aggregates as TLTs.
As ischemic time or the time after IRI increased, TLTs expanded, appeared to destroy adjacent healthy 
nephrons, and occupied larger areas of  the renal parenchyma in aged kidneys (Figure 1, G and I, and 
Supplemental Figure 3I). In contrast, TLT formation was almost undetectable in young kidneys even after 
60-minute IRI, which causes very severe injury (Figure 1, H and I, and Supplemental Figure 3J), suggesting 
that aging itself  is a predisposing factor for TLT formation after kidney injury. Moreover, the expression 
of  Ifng and Tnfa was upregulated in aged kidneys (Figure 1J) and was closely associated with TLT sizes 
(Figure 1K). In 2 other models of  kidney injury, the folic acid (FA) nephropathy model and the unilateral 
ureteral obstruction (UUO) model, TLTs were again found in aged kidneys, but were almost undetectable 
in young kidneys (Figure 1L and Supplemental Figure 4). In the FA nephropathy model, the degree of  
impairment of  renal functions was worse in aged mice and correlated well with TLT size (Figure 1M). 
Thus, TLTs form in aged kidneys after injury, regardless of  the type of  injury, and could serve as a marker 
of  sustained injury and inflammation.
Fibroblasts within TLTs produce homeostatic chemokines. TLT formation mimics, at least in part, the devel-
opmental program of  SLOs (8, 10, 11). Accordingly, we analyzed the renal expression of  the homeostatic 
Downloaded from http://insight.jci.org on July 22, 2016.   http://dx.doi.org/10.1172/jci.insight.87680
3insight.jci.org   doi:10.1172/jci.insight.87680
R E S E A R C H  A R T I C L E
Figure 1. Aged mice develop multiple renal tertiary lymphoid tissues (TLTs) after kidney injury. (A) Periodic acid-Schiff (PAS) staining and (B) fibrosis 
scores 45 days after 30-minute ischemic reperfusion injury (IRI) in young and aged mice (n = 4 per group). (C, E, and F) Immunofluorescence analysis of 
(C) lymphatic vessel endothelial hyaluronan receptor 1 (LYVE1), α-smooth muscle actin (αSMA), and CD45; (E) CD3ε and B220; (F) Ki67 and αSMA; and (D) 
immunohistochemical analysis of peripheral lymph node addressin (PNAd) in inflammatory cell aggregates in aged kidneys at day 45 after 37-minute IRI. 
(G and H) PAS staining of IRI kidneys of (G) aged mice and (H) young mice at day 45, and (I) the TLT sizes (n = 4 or 5 per group). (J) Ifng and Tnfa mRNA 
levels of IRI kidneys at day 45 with variable ischemic times in young and aged mice (n = 4 per group). (K) Correlation between TLT sizes and mRNA levels of 
Ifng and Tnfa in aged IRI kidneys at day 45 with variable ischemic times (n = 16). (L) PAS staining of young and aged kidneys in folic acid (FA) nephropathy 
(day 21) and unilateral ureteral obstruction (UUO) (day 14) model. (M) Serum creatinine (sCr) concentrations in young and aged mice 21 days after FA treat-
ment (n = 12 or 13 per group) and correlation of sCr with TLT size in aged mice (n = 13). *P < 0.001, **P < 0.01, #P < 0.05 versus control. One-way ANOVA with 
Tukey’s post-hoc analysis was used to analyze data from (J); a 2-tailed Student’s t test was used for other experiments. Correlation was determined by 
Pearson’s correlation analysis. Scale bars: (A, C–H, and L) 100 μm. The expression levels were normalized to those of Gapdh and expressed relative to those 
of young mouse kidney at day 0 (IRI). In (B, I, J, and M), the box corresponds to the first quartile, median (horizontal bar in the box), and third quartile, and 
the whiskers extend from minimum to maximum values.
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chemokines CXCL13, CCL19, and CCL21, all 
of  which are essential for SLO development. 
Renal Cxcl13 and Ccl19 expression increased 
dramatically in an ischemic time–dependent 
manner in aged kidneys, but not in young kid-
neys (Figure 2, A and B). Ccl21 expression was 
increased to a lesser extent, although the expres-
sion was comparable between both groups (Fig-
ure 2C). In addition, Cxcl13 and Ccl19 expression 
correlated strongly, whereas Ccl21 expression 
correlated weakly, with the sizes of  TLTs (Figure 
2, D–F). Renal Cxcl13 and Ccl19 expression also 
increased during the course of  TLT formation 
(Supplemental Figure 5).
CXCL13 and CCL19 signals were confined 
within the TLTs (Figure 2, G and H), whereas 
CCL21 signals were detected in lymphatic ves-
sels (Figure 2, I and J). As with SLOs, the renal 
TLTs contained a fibroblast reticular network 
positive for both PDGFRβ and the fibroblast 
marker ER-TR7 (Figure 2, K and L). Notably, 
the CXCL13- and CCL19-positive cells within 
the TLTs were also positive for PDGFRβ and 
ER-TR7, but not for CD45 or CD11c (Figure 2, M–R, and Supplemental Figure 6). These results suggest 
that renal fibroblasts are the main source of  CXCL13 and CCL19 in aged kidneys.
Fibroblasts with distinct phenotypes underlie TLT formation in aged injured kidneys. Crosstalk between lymphoid 
tissue organizer cells and lymphoid tissue inducer cells plays a central role in SLO development (10), and 
this crosstalk is triggered by retinoic acid (RA) released from the neurons (10, 16). While neural fibers in the 
kidney were negative for retinaldehyde dehydrogenase 2 (RALDH2) (Figure 3B), which is the rate-limiting 
enzyme in RA synthesis (17), fibroblasts outside the TLTs were strongly positive for RALDH2 in the early 
Figure 2. Fibroblasts inside tertiary lymphoid tis-
sues (TLTs) produce CXCL13 and CCL19. (A–C) The 
mRNA expression of the homeostatic chemokines 
Cxcl13, Ccl19, and Ccl21 in ischemic reperfusion injury 
(IRI) kidneys 45 days after variable ischemic time 
IRI in young and aged mice (n = 4 per group). The 
expression levels were normalized to those of Gapdh 
and expressed relative to those of young mouse 
kidney at day 0 (IRI). *P < 0.001, **P < 0.01 aged 
versus young (1-way ANOVA with Tukey’s post-hoc 
analysis). The box corresponds to the first quar-
tile, median (horizontal bar in the box), and third 
quartile, and the whiskers extend from minimum to 
maximum values. (D–F) Correlations between TLT 
sizes and mRNA levels of Cxcl13, Ccl19, and Ccl21 
in aged IRI kidneys 45 days after variable ischemic 
time IRI (n = 16). Correlation was determined by 
Pearson’s correlation analysis. (G–R) Immunohis-
tological analysis of aged kidneys 30 days after 
37-minute IRI. Immunofluorescence analysis of (G–I) 
CXCL13, CCL19, and CCL21 with α-smooth muscle 
actin (αSMA); (J) CCL21 and lymphatic vessel endo-
thelial hyaluronan receptor 1 (LYVE1); (K) PDGFRβ; 
(L) ER-TR7; (M–O) PDGFRβ, ER-TR7, and CD45 with 
CXCL13; and (P–R) PDGFRβ, ER-TR7, and CD45 with 
CCL19. Arrows indicate TLT localization. Scale bars: 
(G–I) 100 μm, (K and L) 50 μm, (J, M–R) 10 μm.
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phase of  TLT formation (Figure 3A). Interestingly, the fibroblasts inside the TLTs did not express RALDH2, 
but they did express p75 neurotrophin receptor (p75NTR) (Figure 3A), a marker for the neural crest (18). In 
the early phase of  IRI, p75NTR signals were detectable in the broad area of  the renal interstitium (Figure 3C), 
whereas in the later phase, the signals gradually disappeared in the interstitium and became confined to the 
fibroblasts inside the TLTs (Figure 3D). We previously demonstrated that p75NTR is expressed in fibroblasts 
in neonatal kidneys, but disappears in healthy adult kidneys (19). Fibroblasts inside the TLTs seemed to 
retrieve the phenotype of  the fibroblasts in the neonatal kidneys. RALDH2+ fibroblasts surrounded p75NTR+ 
fibroblasts in TLTs; moreover, RA treatment significantly upregulated the p75ntr expression in C3H10T1/2 
mouse embryonic fibroblasts and FACS-sorted PDGFRβ+ mouse kidney fibroblasts (Figure 3H).
Figure 3. Fibroblasts with distinct phenotypes underlie tertiary lymphoid tissue (TLT) formation in the aged injured 
kidney. Immunofluorescence of (A) retinaldehyde dehydrogenase 2 (RALDH2), p75 neurotrophin receptor (p75NTR), and 
PDGFRβ; (B) β3-tubulin and RALDH2; (C and D) p75NTR; (E) p75NTR and CD21; (F) CD21 and CXCL13; and (G) CD3ε, CD21, 
and B220 in aged kidneys after ischemic reperfusion injury (IRI). Arrows indicate TLT localization. Arrowheads indicate 
the localization of the B cell area. Aged kidneys were analyzed 14 (B and C), 30 (A), and 45 (D–G) days after IRI. (H) Reti-
noic acid (RA) induces p75ntr mRNA expression in C3H10T1/2 mouse embryonic fibroblasts and FACS-sorted PDGFRβ+ 
cells (n = 3 per group). The data are presented as dot plots (mean ± SD). (I) Activation-induced cytidine deaminase (Aid) 
mRNA levels of kidneys 45 days after various ischemic time IRI in young and aged mice (n = 4 per group) and correlation 
with TLT size (n = 16, aged mice only). The expression levels were normalized to those of Gapdh and expressed relative 
to those of controls or young mouse kidney at day 0 (IRI). *P < 0.001 versus controls. A 2-tailed Student’s t test was 
used to analyze data from FACS-sorted PDGFRβ+ cells; 1-way ANOVA with Tukey’s post-hoc analysis was used for other 
experiments. Correlation was determined by Pearson’s correlation analysis. The box corresponds to the first quartile, 
median (horizontal bar in the box), and third quartile, and the whiskers extend from minimum to maximum values. 
Scale bars: (A, C, and D) 100 μm, (E and G) 50 μm, (B and F) 10 μm.
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In the later phase of  the injury, p75NTR-negative areas began to appear within the TLTs, and CD21+ 
stromal cells emerged and compensated for the p75NTR-negative areas (Figure 3E). CD21+ stromal cells 
expressed CXCL13 (Figure 3F) and formed B cell areas (Figure 3G), indicating the development of  follicu-
lar dendritic cells (FDCs), which are conventional CXCL13-producing stromal cells found in SLOs (20), 
as a part of  the stromal network. FDCs are known to support germinal center responses in SLOs, and the 
expression of  activation-induced cytidine deaminase (Aid), which is essential for both somatic hypermuta-
tion and class switch recombination in germinal center B cells (21), increased in an ischemic time–depen-
dent manner and correlated closely with TLT size in aged kidneys (Figure 3I). These results suggest that a 
germinal center response may occur during the later phase of  TLT formation.
Heterogeneous fibroblasts involved in TLT formation are derived from a single lineage. Although the phenotypic diver-
sity of fibroblasts associated with TLTs was established above, the origin of these heterogeneous fibroblasts was 
still unknown. We previously showed that renal resident fibroblasts in the cortex and outer medulla are lineage-
labeled with myelin protein zero-Cre (P0-Cre; a Cre strain that expresses Cre in the migrating neural crest and 
Schwann cells; see ref. 22) and that P0-Cre lineage-labeled resident fibroblasts transdifferentiate into αSMA+ 
myofibroblasts and drive renal fibrosis in the injured kidney (19, 23). To examine the contribution of P0-Cre 
lineage-labeled resident fibroblasts to the heterogeneous fibroblasts in TLTs, we used P0-Cre:R26ECFP mice to 
trace the lineage of these fibroblasts. We found that almost all PDGFRβ+ fibroblasts both inside and outside of  
TLTs, as well as p75NTR+, RALDH2+, CXCL13+, CCL19+, and CD21+ fibroblasts, were lineage-labeled with 
P0-Cre (Figure 4, A–I). These data support the idea that P0-Cre lineage-labeled fibroblasts diversify into hetero-
geneous fibroblasts with several different phenotypes in response to their microenvironment, and also under-
lie TLT formation. Neither Cre protein nor P0 and Cre mRNA was detected in aged P0-Cre:R26ECFP kidneys 
(Supplemental Figure 7), thereby excluding the possibility of Cre reactivation in the kidneys with TLTs.
Figure 4. Myelin protein zero-Cre (P0-Cre) lineage-labeled fibroblasts differentiate into diverse fibroblasts with distinct 
phenotypes. (A–I) Immunofluorescence (IF) of enhanced cyan fluorescent protein–positive (ECFP+) cells in kidneys sub-
jected to ischemic reperfusion injury (IRI) in aged P0-Cre/R26ECFP mice. ECFP was visualized with an anti-GFP antibody. 
IF of GFP and (A and D) PDGFRβ, (B and E) p75 neurotrophin receptor (p75NTR), (C and F) retinaldehyde dehydrogenase 2 
(RALDH2), (G) CXCL13, (H) CCL19, and (I) CD21. Magnified views of the outlined regions in (A–C) are shown in (D–F), respec-
tively. Arrows in (A–C) indicate tertiary lymphoid tissue (TLT) localization. Scale bars: (A–C) 50 μm, (D–I) 10 μm.
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Superaged mice spontaneously develop TLTs without injury. Aging is often accompanied by chronic inflam-
mation that leads to a functional decline in various organs (24). Even without kidney injury, superaged 
mice developed renal TLT-like structures (Figure 5, A–C), which entangled the glomeruli and tubules 
inside (Figure 5A) and appeared to damage adjacent tubules (Figure 5, B and C). As with the TLTs in 
aged injured kidneys, these structures surrounded the interlobular artery and lymphatic vessel endothelial 
hyaluronan receptor 1+ (LYVE1+) lymphatic vessels (Figure 5D). These TLT-like structures were composed 
mainly of  T cells and B cells (Figure 5E), some of  which were Ki67+ (Figure 5F), thereby defining these 
Figure 5. Superaged mice spontaneously develop renal tertiary lymphoid tissues (TLTs) without injury. (A–I) Histological 
analysis of a 23-month-old mouse kidney. (A) Periodic acid-methenamine silver (PAM) staining showing a TLT containing 
PAM-positive basement membranes of nephron segments. (B and C) PAS staining showed signs of injury (yellow arrows) 
in tubules adjacent to TLTs. A magnified view of the outlined region in B is shown in C. (D–I) Immunofluorescence analysis 
of (D) lymphatic vessel endothelial hyaluronan receptor 1 (LYVE1), α-smooth muscle actin (αSMA), and CD45; (E) CD3ε and 
B220; (F) Ki67; (G) p75 neurotrophin receptor (p75NTR); (H) CXCL13 and αSMA; and (I) CCL19 and αSMA. White arrows indi-
cate the localization of TLTs. Scale bars: (A, B, D, F, G, and I) 100 μm, (C, E, and H) 50 μm. (J) The expression of Cxcl13, Ccl19, 
Ifng, and Tnfa mRNA in mouse kidneys at various ages (n = 4 per group). The expression levels were normalized to those of 
Gapdh and expressed relative to those of young (2-month-old) mouse kidneys. In J, the box corresponds to the first quartile, 
median (horizontal bar in the box), and third quartile, and the whiskers extend from minimum to maximum values.  
*P < 0.001, **P < 0.01, #P < 0.05 versus values at 2 months of age (2-tailed Student’s t test).
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Figure 6. Targeting tertiary lymphoid tissue (TLT) formation has the potential to ameliorate renal fibrosis and inflammation. (A–C) Analysis of the 
kidneys from aged CXCL13-deficient mice (KO) and their littermates (WT) 45 days after ischemic reperfusion injury (IRI) (n = 6 per group). (A) Periodic acid-
Schiff (PAS) staining, (B) TLT sizes, and (C) Ccl19 and Ifng mRNA levels in IRI kidneys. (D–H) GK1.5 treatment study (n = 5 or 6 per group). (D) Experimental 
protocol, (E) PAS staining, (F) TLT sizes, (G) fibrosis scores, (H) Cxcl13, Ccl19, Ifng, Tnfa, Col1a1 (type 1 collagen α-1 subunit), and Fn1 (fibronectin) mRNA 
levels in the IRI kidneys of GK1.5-treated mice (GK1.5) and isotype antibody–treated mice (Isotype control, Con). (I–M) Dexamethasone (Dex) treatment 
study (n = 5 per group). (I) Experimental protocol, (J) PAS staining, (K) TLT sizes, (L) fibrosis scores, and (M) Cxcl13, Ccl19, Ifng, Tnfa, Col1a1, and Fn1 mRNA 
levels in the IRI kidneys of Dex-treated (DEX) and vehicle-treated mice (Control, Con). Mice were subjected to 37-minute IRI (A–C) or 30-minute IRI (D–M). 
The expression levels were normalized to those of Gapdh and expressed relative to those of aged (12-month-old) mouse kidney. The box corresponds to 
the first quartile, median (horizontal bar in the box), and third quartile, and the whiskers extend from minimum to maximum values. *P < 0.001, **P < 0.01, 
#P < 0.05 versus control (2-tailed Student’s t test). n.s, not significant. Scale bars: (A, E, and J) 100 μm.
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aggregates as TLTs. These TLTs also harbored a p75NTR+ fibroblast network (Figure 5G) and CXCL13+ 
and CCL19+ cells (Figure 5, H and I). In addition, the renal expression of  Cxcl13, Ccl19, Ifng, and Tnfa was 
upregulated in an age-dependent manner (Figure 5J). Taken together, these data indicate that superaged 
mice spontaneously formed TLTs without injury, and that these were phenotypically equivalent to those in 
the aged injured kidney.
Targeting TLT formation has the potential to ameliorate renal fibrosis and inflammation. To assess the contribu-
tion of  TLTs to long-term outcomes after kidney injury, we set up a series of  experiments that could prevent 
the formation of  renal TLTs after kidney injury in aged mice. First, we evaluated whether the loss of  CXCL13 
affects TLT formation. IRI-induced TLTs were smaller in aged CXCL13-deficient mice (Figure 6, A and B) 
than wild-type littermates, although TLTs had similar cellular components (Supplemental Figure 8). Further-
more, the expression of  Ccl19 and Ifng was significantly reduced in the CXCL13-deficient mice (Figure 6C).
Figure 7. Tertiary lymphoid tissues (TLTs) form in aged human kidneys. (A–L) Histological analyses of aged 
human kidney samples. (A and B) Periodic acid-Schiff (PAS) staining and immunofluorescence analysis of (C) CD20 
and CD3ε; (E) Ki67 and CD3ε/CD20 (arrowheads indicate double-positive cells); (G) CXCL13 and CD21; (J) CXCL13 and 
CD45; (K) CD21, α-smooth muscle actin (αSMA), and CD45; and (L) p75 neurotrophin receptor (p75NTR) and CD21, 
and immunohistochemical analysis of (D) peripheral lymph node addressin (PNAd); (F) CD21 (arrowheads indicate 
the localization of CD21+ follicular dendritic cell [FDC] networks); (H) CD20, activation-induced cytidine deaminase 
(AID), CD21, and retinaldehyde dehydrogenase 2 (RALDH2) (serial sections); and (I) RALDH2 (arrowheads indicate 
the localization of B cell follicles). The outlined region in (H) is magnified in (I). Arrows indicate TLT localization. 
Scale bars: (A, D, H, K, and L) 50 μm, (B, C, and F) 100 μm, (E, G, I, and J) 10 μm. (M) Quantitative analysis of TLT 
frequencies in human samples (n = 56; young = 13, aged = 43). #P < 0.05 (Pearson’s χ2 test).
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Second, to test whether TLT formation depends on CD4+ cells, which are the major component of  
renal TLTs (Supplemental Figure 3A), we depleted CD4+ cells using the anti-CD4 monoclonal antibody 
GK1.5 (Figure 6D). We confirmed the depletion of  CD4+ cells in the kidney and in the peripheral blood 
(Supplemental Figure 9). Mice treated with an isotype control antibody developed robust TLTs, where-
as mice treated with GK1.5 did not develop TLTs (Figure 6, E and F), suggesting that TLT formation 
depended on CD4+ cells. Fibrosis score and the expression of  homeostatic chemokines, proinflammatory 
cytokines, and fibrosis markers were significantly reduced in the GK1.5-treated kidneys (Figure 6, G and 
H), suggesting that the deletion of  TLTs could improve renal outcomes.
Third, we examined whether targeting the inflammatory microenvironment could suppress TLT-
associated pathological conditions and improve renal outcomes. In most clinical situations, triggers of  
AKI, such as ischemic damage, arise without forewarning. We therefore administered dexamethasone 
(Dex) 2 weeks after ischemic insults (Figure 6I) and found that TLT formation was abolished and tubular 
injury was significantly attenuated in Dex-treated kidneys (Figure 6, J and K). Dex-treated mice exhib-
ited a tendency to be less fibrotic than control mice, and the expression of  homeostatic chemokines, pro-
Figure 8. A model for renal tertiary lymphoid tissue (TLT) formation. Heterogeneous fibroblasts play crucial roles in steering the development and 
maturation of renal TLTs in mice and humans. (A) Mouse: In the early stage, fibroblasts around arteries receive retinoic acid (RA) from retinaldehyde 
dehydrogenase 2+ (RALDH2+) fibroblasts in a paracrine manner and dedifferentiate into p75 neurotrophin receptor+ (p75NTR+) fibroblasts, some of 
which acquire the ability to produce CXCL13/CCL19 (Stage 1). As the TLT grows and expands, the number of RA-producing fibroblasts around it gradu-
ally decreases (Stage 2). In this stage, CD21+/p75NTR– follicular dendritic cells (FDCs) emerge as a part of a stromal network, and peripheral lymph node 
addressin+ (PNAd+) high endothelial venules (HEVs) develop within the TLT. Human: Although the major components in human renal TLTs are quite simi-
lar to those in mouse TLTs, p75NTR colocalizes with CD21, and RALDH+ stromal cells surrounded these FDC networks. (B) A model of stromal cell matura-
tion in the aged injured kidney. Upon kidney injury, resident fibroblasts differentiate into RALDH+ fibroblasts, which promote the transdifferentiation of 
other fibroblasts into p75NTR+ fibroblasts with 3 phenotypes. These p75NTR+ fibroblasts act in concert to form TLTs. In the later phase of kidney injury, 
some of these fibroblasts lose their p75NTR expression and mature into CD21+/CXCL13+/p75NTR– FDCs.
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inflammatory cytokines, and fibrosis markers was also significantly reduced in Dex-treated mice (Figure 
6, L and M), suggesting that antiinflammatory therapy could have the therapeutic potential to improve 
renal outcomes after AKI in the elderly by suppressing TLT-mediated inflammation.
TLTs form in aged human kidneys. Finally, we investigated whether our observations in mouse kidneys 
are relevant to human kidneys. In aged human kidneys, we found various degrees of  chronic infiltrates 
around the arteries (Figure 7A), some of  which harbored germinal center–like structures (Figure 7B). These 
human TLTs, like mouse TLTs, were composed mainly of  T cells and B cells (Figure 7C) and contained 
HEVs (Figure 7D). Ki67 signals were also detectable within the aggregates (Figure 7E), suggesting that 
some of  the chronic infiltrates functioned as TLTs. Some TLTs contained CD21+ FDC networks (Figure 
7F) that were positive for CXCL13 (Figure 7G). Similar to our findings in mice, the CXCL13-positive cells 
were negative for CD45 (Figure 7J). Furthermore, AID was expressed within the B cell area in some TLTs 
(Figure 7H). As in mouse TLTs, fibroblasts outside the human renal TLTs had completely different pheno-
types from those inside (Figure 7K). Unlike mouse renal TLTs, we found that p75NTR colocalized with 
CD21, an FDC marker, in human renal TLTs (Figure 7L), and RALDH+ stromal cells surrounded these 
FDC networks (Figure 7, H and I), suggesting that, as in mouse renal TLTs, RA might play a crucial role 
in inducing p75NTR expression in human renal TLTs, especially in the development of  FDC networks.
In specimens from 56 kidneys from patients (Supplemental Table 1), human TLTs, defined as inflam-
matory cell aggregates with CXCL13- and Ki67-positive signals inside, were significantly more prevalent in 
aged patients (over 60 years old, 28%) than in young patients (under 40 years old, 0%) (Figure 7M).
Discussion
Although epidemiological data established the relationship between AKI and subsequent CKD/ESRD 
(1–3, 5), there still has been no effective treatment and biomarker for the patients who progress to CKD/
ESRD after AKI. In the present study, we showed that, after kidney injury, TLTs developed within the 
kidney in an age-dependent manner and played pathogenic roles for the host in mouse and human. Our 
finding could lead to new treatment strategies and approaches to triage patients who have survived AKI, 
and potentially improve renal outcome in the aged AKI patients.
In this report, we defined TLTs as the organized lymphocyte aggregates composed of  T cells and 
B cells with signs of  proliferation. The definition of  TLTs also includes the production of  homeostatic 
chemokines such as CXCL13 and CCL19 inside TLTs. While HEVs and CD21+ FDCs were observed 
in larger TLTs, these findings were not included in the definition of  TLTs, because small TLTs did not 
show these structures.
The developmental origin and phenotypic heterogeneity of  stromal cells in TLTs have not been clari-
fied due to the limitation of  in vivo models (25, 26). Most in vivo TLT models are organ-specific transgenic 
mouse models ectopically expressing molecules stimulating TLT formation, which are artificial and inca-
pable of  fully mimicking the pathophysiology of  TLTs. In the present study, we established a potentially 
novel model of  inducible, sterile TLT formation, which has provided a solution to this limitation. This 
model and the genetic lineage-tracing method enabled us, for what we believe is the first time, to conduct 
a detailed analysis of  the stromal cells underlying TLT formation, and we believe this is the first study that 
directly demonstrates the developmental origin of  stromal cells, including FDCs, in TLTs.
The formation of  TLTs in the inflamed organs has been associated with both protective and deleterious 
outcomes for the host (8–11). We demonstrated the direct destruction of  neighboring parenchyma around 
renal TLTs, the close association between TLT sizes and impaired renal function, as well as renal expres-
sion of  proinflammatory cytokines and AID, both of  which support the notion that TLTs are detrimental 
to the aged injured kidney. Our findings indicate that the TLTs in aged kidneys are aberrant immuno-
logical foci, where pathogenic immune responses are generated. T cells, especially CD4+ T cells, were also 
observed around the TLTs, whereas most B cells were confined within the TLTs in the later phase in aged 
IRI kidneys (Supplemental Figure 10), suggesting that TLT-derived T cells might propagate inflammation 
across the entire kidney. In addition, the close association between TLT sizes and AID expression suggests 
that B cells might activate the molecular machinery responsible for producing affinity-maturated antibodies 
within the renal TLTs. Indeed, TLTs have been shown to support autoantibody production (27, 28), and 
the presence of  TLTs predicts a poor outcome for chronic rejection (29, 30) and autoimmune disease (31). 
The presence of  TLTs in the patients with IgA nephropathy, which is not age dependent, has also been cor-
related with poor renal outcomes (32).
Downloaded from http://insight.jci.org on July 22, 2016.   http://dx.doi.org/10.1172/jci.insight.87680
1 2insight.jci.org   doi:10.1172/jci.insight.87680
R E S E A R C H  A R T I C L E
TLTs in the aged injured kidney exist in various stages of  maturation (Figure 8A). In the early stage of  
TLT formation (Stage I), fibroblasts around arteries receive RA from RALDH+ fibroblasts in a paracrine 
manner and dedifferentiate into p75NTR+ fibroblasts, some of  which acquire the ability to produce homeo-
static chemokines (CXCL13/CCL19) (Figure 8, A and B). As the TLT grows and expands, the number of  
RA-producing fibroblasts around the TLT gradually decreases (Stage II). In this stage, CD21+ p75NTR– 
FDCs emerge as a part of  a stromal network, and peripheral lymph node addressin+ (PNAd)+ HEVs develop 
within the TLT. Importantly, TLTs were also observed in the aged but not young human kidneys, and the 
cellular and molecular components of  these TLTs had strong similarities to mouse TLTs (Figure 8A). Thus, 
age-dependent renal TLT formation appears to be conserved across species, and the mechanism involved 
in the progression of  human kidney disease in the elderly may be similar to that in aged mice. Notably, 
although renal TLTs have been reported only in patients with immune-medicated conditions, such as auto-
immune disease, chronic rejection, glomerulonephritis, and infections (29, 32, 33), we found age-dependent 
renal TLTs not only in the patients with the diseases above, but also in various types of  kidney disease such as 
diabetic nephropathy and benign nephrosclerosis, indicating the universality of  TLT formation with aging.
To define the cellular origin of  TLT-associated fibroblasts described above, we performed a lineage-
tracing analysis utilizing P0-Cre mice, and for the first time to our knowledge, demonstrated that these 
TLT-associated heterogeneous fibroblasts, including FDCs, are derived from resident fibroblasts in the 
kidney (Figure 8B). This is consistent with a previous report that FDCs in the spleen arise from a sub-
population of  PDGFRβ+ resident stromal cells in the spleen after inflammatory stimuli (34). Our data 
not only add concrete evidence showing that FDCs originate from PDGFRβ+ resident fibroblasts, but 
also suggest the developmental origin of  FDCs through the lineage-tracing analysis with P0-Cre mice, 
which express Cre in the migrating neural crest and Schwann cells (22). Very recently, FDCs in the 
lymph node were reported to be lineage-labeled with Wnt-1 Cre (35), another Cre strain that labels neu-
ral crest–derived cells. Together with our findings in this study, these data suggest that, depending on 
the microenvironment, neural crest–derived cells have the potential to become homeostatic chemokine–
producing fibroblasts, including FDCs. Of  note, p75NTR+ CCL19-producing fibroblasts inside TLTs, 
which may be the intermediate cellular elements capable of  maturing into another stromal cell in TLTs, 
fibroblastic reticular cells (36), also simultaneously arise from P0-Cre lineage-labeled resident fibroblasts.
We further demonstrated that a paracrine interaction between fibroblasts with distinct phenotypes trig-
gers the initiation of  TLT formation. The reciprocal expression pattern of  RALDH and p75NTR in mouse 
and human TLTs (Figure 8A) and an in vitro experiment (Figure 3H) indicates that fibroblast-derived RA 
promotes the expression of  p75NTR in the fibroblasts inside TLTs to become the producer of  CXCL13, 
whereas neuron-derived RA drives the expression of  CXCL13 in lymphoid tissue organizer cells during 
the initiation of  SLOs (16). To our knowledge, this is the first time that the involvement of  RA has been 
demonstrated in the initiation of  TLT formation.
The exclusive expression pattern of  p75NTR in the fibroblasts inside TLTs led us to hypothesize that 
fibroblast phenotypes are determined by the microenvironment in which they reside. Notably, a novel lym-
phoid stromal cell type that can adapt its secretion of  homeostatic chemokines according to its cellular 
environment was recently identified in the lymph node (37). Together, these data suggest that the phenotype 
of  fibroblasts is plastic, and the regional microenvironments are critical determinants of  their phenotype 
and could therefore be a therapeutic target.
Based on these observations, we conducted a series of  interventional studies at molecular, cellular, 
and microenvironmental levels, to investigate the contribution of  TLTs to disease progression in aged 
injured kidneys.
Smaller TLTs formed in aged CXCL13-deficient mice than in their wild-type littermates, suggesting that 
CXCL13 is crucial, although also redundant, for TLT formation in aged kidneys. The absence of  lymph 
nodes in CXCL13-deficient mice (38) might also affect the severity of  IRI, since lymph nodes play a crucial 
role in IRI pathophysiology (39). Further studies are required to determine whether CXCL13 is a suitable 
therapeutic target.
Furthermore, we found that depleting CD4+ cells abolished TLTs and resulted in the resolution of  renal 
inflammation and fibrosis, suggesting that TLTs contribute to the sustained inflammation and impaired 
regeneration after AKI in the elderly. The significant contribution of  CD4+ cells to TLT formation is con-
sistent with previous reports in other TLT models (40–42). Among various types of  immune cells, age-
dependent proportional and phenotypic changes of  CD4+ T cells are most prominent, because of  thymic 
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involution with aging (24). Reduced thymic output results in lymphopenia, leading to a global phenotype 
shift from naive to memory T cells. Indeed, a bona fide, age-dependent, unique memory phenotype CD4+ T 
cell subpopulation was identified (43), which produces osteopontin and sclerostin domain–containing pro-
tein 1 (Sostdc1), also known as uterine sensitization–associated gene-1 (USAG-1), a novel BMP antagonist 
negatively regulating the renoprotective effect of  BMP that we recently identified (44–47). The contribution 
of  various types of  CD4+ T cells to TLT formation should be analyzed in future studies.
Most importantly, we showed that administering Dex halted TLT formation and attenuated renal 
inflammation and fibrosis, even with late administration. Very recently, a single intraoperative, prophylac-
tic treatment of  high-dose Dex was found to effectively reduce the incidence of  severe AKI after cardiac 
surgery in patients with advanced CKD (48); thus, Dex might also be a therapeutic option for AKI. Dex 
affects multiple types of  cells and can dampen pathogenic immune responses directly or indirectly at mul-
tiple levels, although this amelioration is accompanied by side effects such as infections and diabetes.
Identifying patients at high risk for progressing to CKD/ESRD after AKI has the potential to reliably 
improve the treatment for these patients. Identifying the molecules involved in TLT formation will yield 
biomarkers with the requisite specificity to select groups of  patients with TLTs and sustained inflammation. 
Implementation of  such biomarker tests based on TLT-associated molecules may enable us to consider 
earlier clinical assessment, intervene in the patients at high risk for CKD/ESRD progression with currently 
available immunosuppressive agents such as Dex, and transfer patients to higher levels of  care, therefore 
yielding improved outcomes. It is also important to acknowledge that future therapeutic strategies target-
ing the molecules and cell types specific for TLT formation might allow us to delete TLT more specifically 
and circumvent serious side effects of  currently available immunosuppressive agents. Further studies are 
warranted to elucidate the molecular and cellular basis underlying TLT formation and establish biomarkers 
for selecting the patients developing TLTs, for translation of  TLT-targeting therapies to human subjects.
Our data suggest a crucial role for RA in the initial step of  TLT formation. While endogenous RA 
signaling was recently reported to have a reno-protective effect (49, 50), RA in the aged kidneys can trigger 
TLT formation, which promotes inflammation and hinders regeneration. Thus, RA’s role in the injured 
kidney appears to be context dependent. Further understanding of  the regulatory mechanism of  RA pro-
duction may therefore provide novel insight into adaptive and maladaptive repair after kidney injury.
Our study has limitations. First, neither the administration of  GK1.5 nor Dex treatment is specific for 
TLT depletion. Depleting TLTs without affecting the entire immune system has been technically challeng-
ing because of  the significant overlap in the mechanisms of  SLO development and TLT formation, render-
ing the interpretation of  the effects of  TLT on the underlying disease difficult. In addition, it is still unclear 
why the renal environment becomes prone to TLT formation with aging.
In the present study, we shed light on the mechanisms underlying maladaptive repair in aged injured 
kidneys and identified previously unrecognized, age-dependent, pathogenic renal TLTs in mice and 
humans that have potential therapeutic relevance. Our findings indicate that TLTs could be a new target 
of  therapeutic intervention for AKI in the elderly, and unraveling the cell types and molecules that govern 
TLT formation will open up a new avenue for overcoming kidney diseases in the elderly.
Methods
Animals. We selected 8-week-old, 12-month-old, and 23-month-old C57BL6J male mice as the young, aged, 
and superaged models, respectively, and purchased the mice from Japan SLC. P0-Cre (on an ICR back-
ground) mice (22) and R26ECFP (on a C57BL6 background) mice (51) were kindly provided by Kenichi 
Yamamura (Kumamoto University, Kumamoto, Japan) and Frank Costantini (Colombia University, New 
York, New York, USA), respectively. CXCL13-deficient mice (on a C57BL6 background) were described 
previously (52) and WT littermates were used as controls. Serum creatinine was measured by the creatini-
nase-HMMPS method (SRL). All mice were maintained in specific pathogen–free conditions in the animal 
facility of  Kyoto University. All animal experiments were approved by the Animal Research Committee, 
Graduate School of  Medicine, Kyoto University, and were conducted in accordance with the Guide for the 
Care and Use of  Laboratory Animals (NIH).
Kidney injury models. IRI, UUO, and FA nephropathy were induced as described previously (45, 46, 
53). Briefly, IRI was induced by clamping unilateral renal pedicles for various lengths of  time. Each 
group included at least 4 mice. In the FA nephropathy model, young (n = 12) and aged (n = 13) mice 
received FA (250 mg/kg; catalog F8758-25G; Sigma-Aldrich) in 0.15 M NaHCO3 on day 0 and were 
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euthanized on day 21. Mice subjected to UUO were euthanized 14 days after the operations (n = 4 in 
each group).
Renal histochemistry. Mouse kidneys were harvested, cut along the short axis at the maximum area of  
the whole kidney, fixed in Carnoy’s solution, embedded in paraffin, sectioned (2.0-μm thickness), and then 
stained with periodic acid-Schiff  (PAS) or periodic acid-methenamine-silver (PAM). Human kidneys were 
fixed in formalin, embedded in paraffin, sectioned (3.0-μm thickness), and stained with PAS.
Renal immunofluorescence. For immunofluorescence studies of mouse kidneys, the kidneys were fixed in 4% 
paraformaldehyde, incubated in 20% sucrose for 6 hours, and incubated in 30% sucrose in PBS at 4°C overnight. 
OCT-embedded (Sakura Finetek) kidneys were cryosectioned into 6.0-μm sections and mounted on Superfrost 
slides (Matsunami Glass). Sections were blocked with 5% serum appropriate for the secondary antibody for 1 
hour at room temperature, and then were incubated overnight at 4°C with primary antibodies. The following 
primary antibodies were used in the mouse immunohistochemistry and immunofluorescence experiments: 
anti-αSMA (catalog C6198; Sigma-Aldrich), -AID (catalog 4959; Cell Signaling), -GFP (catalog ab13970; 
Abcam), -Ki67 (catalog 14-5698; eBioscience), -CD45 (catalog 14-0451; eBioscience), –CD11c-PE (catalog 
12-0114; eBioscience), –PDGFR-β (catalog 14-1402; eBioscience), –β3tubulin-FITC (catalog A488-435L; 
Covance), -Cre (catalog 69050-3; Novagen), –LYVE-1 (catalog ab14917; Abcam), -CD21 (catalog ab75985; 
Abcam), –ER-TR7 (catalog T-2109; BMA Biomedicals), -CXCL13 (catalog AF470; R&D Systems), -CCL19 
(catalog AF880; R&D Systems), -CCL21 (catalog AF457; R&D Systems), - p75NTR (catalog AF1157; R&D 
Systems), -CD3ε (catalog 550275; BD PharMingen), -B220 (catalog 557390; BD PharMingen), –PD-1 (catalog 
114102; BioLegend), -CD4 (catalog 100726; BioLegend), -CD8 (catalog 100425; BioLegend), -PNAd (catalog 
120801; BioLegend), and -ALDH1A2 (catalog HPA010022; Sigma-Aldrich) antibodies. ECFP was visualized 
with the anti-GFP antibody.
For immunofluorescence studies of  human kidneys, kidney sections were fixed in formaldehyde and 
embedded in paraffin. The paraffin-embedded sections were deparaffinized with xylene, rehydrated, and 
then steam heated for 15 minutes. The sections were incubated with 5% serum appropriate for the sec-
ondary antibody for 1 hour at room temperature, and then were incubated overnight at 4°C with pri-
mary antibodies as follows: anti-CD20 (catalog 14-0202; eBioscience), -CD45 (catalog 14-9457; eBiosci-
ence), -p75NTR (catalog AF1157; R&D Systems), -PNAd (catalog 120801; BioLegend), -ALDH1A2 
(catalog HPA010022; Sigma-Aldrich), -CD3ε (catalog ab5690; Abcam), -CD21 (catalog ab75985; Abcam), 
-CXCL13 (catalog AF801; R&D Systems), -Ki67 (catalog NCL-Ki67p; Vision BioSystems), and -αSMA 
(catalog C6198; Sigma-Aldrich) antibodies. Staining was visualized using the appropriate secondary anti-
bodies. Slides were counterstained with DAPI. All of  the immunofluorescence samples were analyzed with 
a confocal microscope (FV1000D; Olympus).
Renal immunohistochemistry. For immunohistochemistry, mouse and human kidneys were prepared 
as described above for the immunofluorescence studies of  human kidneys. Endogenous peroxidase was 
blocked using 3% H2O2. Antibody labeling was detected using a diaminobenzidine substrate kit (Vector 
Laboratories). Sections were counterstained with hematoxylin. The colocalization of  CD20, CD21, and 
AID was determined by the staining of  serial sections. All of  the immunohistochemistry samples were 
analyzed with a Zeiss Axio Imager A2 microscope using Zeiss Axio Vision 4.8 software.
Quantitative analysis for renal fibrosis. For the quantitative analysis of  renal fibrosis, the fibrotic area in 
Masson trichrome–stained sections was quantified using Adobe Photoshop software (Adobe) by determin-
ing the number of  pixels present in the interstitial fibrotic area. The average ratios of  fibrotic area to each 
microscopic field from the 8 images was calculated for each sample and expressed as the percentage area.
Quantification of  TLT size. The renal TLT sizes were examined in PAS-stained sections of  injured kid-
neys. TLT size was defined as the total cumulative size of  the TLTs in the renal cortex of  the sample. 
Pictures that included TLTs were taken at the same size and resolution, and TLT size was measured by an 
experienced renal pathologist using Adobe Photoshop software.
Real-time RT-PCR analysis. RNA extraction and real-time RT-PCR were performed as described previ-
ously (45, 46). The primer sequences are listed in Supplemental Table 2. Expression levels were normalized 
to those of  Gapdh and expressed relative to levels in the young mouse kidney on day 0 (IRI) (Figures 1, 2, 
3I, and 5), aged mouse kidney on day 0 (IRI) (Figure 6), or in controls (Figure 3H).
GK1.5 administration. GK1.5 (catalog 40-0041; Tonbo Biosciences) (150 μg, n = 5) or isotype-matched 
control immunoglobulin G (catalog 400640; clone RTK4530; BioLegend) (150 μg, n = 6) was adminis-
tered to aged mice by intraperitoneal injection 2 days before and at 8, 22, and 35 days after unilateral 
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30-minute IRI. Mice were euthanized 45 days after IRI. The efficacy of  CD4+ cell depletion was con-
firmed by flow cytometric analysis of  peripheral blood cells and by immunostaining for CD4 in kidney 
samples harvested on day 45.
Dex administration. Mice underwent 30-minute IRI on day 0 and received 8 mg/kg Dex (MSD) (n = 5) 
or PBS (n = 5) intraperitoneally on days 14, 15, and 16. On day 17, an osmotic minipump (model 2001; 
Alzet) with either Dex (79.2 μg/day) or PBS vehicle was placed in a subcutaneous pouch. Mice were eutha-
nized 24 days after IRI.
Flow cytometric analysis. Red blood cells were lysed with ACK lysis buffer (0.15 M NH4Cl, 10 mM 
KHCO3, 0.1 mM Na2EDTA, pH 7.2–7.4), and the remaining single-cell suspensions were blocked 
with anti-CD16/32 antibody (clone 2.4G2) and then stained with PE-conjugated anti-CD3ε (catalog 
15-0031-83; eBioscience), FITC-conjugated anti-TCRβ (catalog 109206; BioLegend), PE-Cy7-conju-
gated anti-CD4 (catalog 60-0041-U100; Tonbo Bioscience), and APC-conjugated anti-CD8 antibod-
ies (catalog 20-1886-U100; Tonbo Bioscience). All flow cytometric analyses were performed using a 
FACSCanto (BD Bioscience).
Cell culture experiments. C3H10T1/2 cells were purchased from the Health Science Research Sources 
Bank (Osaka, Japan). Renal PDGFRβ+ fibroblasts were sorted as described previously (19), using a PE-con-
jugated anti-PDGFRβ antibody (catalog 12-1402; eBioscience). Both cell types were cultured with DMEM 
supplemented with 10% FCS and were treated with vehicle (ethanol) or with 25 nM or 50 nM RA (catalog 
R2625-50MG; Sigma-Aldrich) for 9 hours.
Analysis of  human kidney specimens. All of  the human specimens were procured and analyzed after 
informed consent and with approval of  the Ethics Committee of  Kyoto University Hospital. Kidneys 
from nephrectomy cases for renal cell carcinoma and from autopsy cases in Kyoto University Hospital 
were analyzed. Experienced pathologists confirmed that all of  the nephrectomy samples analyzed in this 
study were free of  carcinoma. For the quantitative analysis of  TLT formation frequencies, kidneys from 47 
nephrectomy cases for renal cell carcinoma and from 9 autopsy cases in Kyoto University Hospital were 
analyzed. Because TLTs can develop as a result of  certain diseases, patients who had a clinical history and/
or laboratory evidence of  the following diseases were excluded: (a) pyelonephritis, (b) glomerulonephritis, 
(c) autoimmune kidney disease, and (d) hematological malignancies. We defined young patients as those 
40 years of  age and under, and aged patients as those 60 and over. Clinical data including medical history, 
complications, and laboratory data are detailed in Supplemental Table 1. To discriminate between chronic 
infiltrates and TLTs in human samples, the TLTs were defined as mononuclear perivascular cell aggregates 
that contained both CXCL13 and Ki67 signals. An experienced renal pathologist assessed the frequency of  
TLTs in each specimen.
Statistics. Data are reported as dot plots with the average ± SD or as box and whisker plots. Statistical 
significance was assessed by a 2-tailed Student’s t test for comparisons between 2 groups, 1-way ANOVA 
with Tukey’s post-hoc tests for comparisons among more than 2 groups, and Pearson’s χ2 test in Figure 
7M and Supplemental Table 1. Correlations were determined by Pearson’s correlation analysis. Statistical 
analyses were performed using JMP software (version 9.0). For all analyses, we considered P values less 
than 0.05 to be statistically significant.
Study approval. All animal experiments were approved by the Animal Research Committee, Graduate 
School of  Medicine, Kyoto University, and were conducted in accordance with the Guide for the Care 
and Use of  Laboratory Animals (NIH). All of  the human specimens were procured and analyzed after 
informed consent and with approval of  the ethical committee of  Kyoto University Hospital.
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